Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4019-4025

  Clement, I P ^a   Lisk, Donald J ^b   Ganther, Howard E ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer prevention; Diphenyl selenide; Methylphenyl selenide; p xylylbis(methylselenide); Triphenylselenonium chloride

Indexed keywords

4 XYLYLBIS(METHYLSELENIDE); DIPHENYL SELENIDE; METHYLPHENYLSELENIDE; SELENIUM; SELENIUM DERIVATIVE; SELENOPROTEIN; TRIPHENYLSELENONIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LIPOPHILICITY; LIVER; MAMMARY GLAND; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMOPREVENTION; DIETARY SUPPLEMENTS; FEMALE; KIDNEY; LIVER; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLIC CLEARANCE RATE; METHYLNITROSOUREA; ORGANOSELENIUM COMPOUNDS; PROTEIN BIOSYNTHESIS; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SELENOPROTEINS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 0032423649     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ip C, Thompson H and Ganther H: Activity of triphenylselenonium chloride in mammary cancer prevention. Carcinogenesis 15: 2879-2882, 1994.
2. Ip C, Lisk DJ, Ganther H and Thompson HJ: Triphenylselenonium and diphenylselenide in cancer chemoprevention: Comparative studies of anticarcinogenic efficacy, tissue selenium levels and excretion profile. Anticancer Res 17: 3195-3200, 1997.
3. Ip C, Thompson HJ and Ganther HE: Cytostatis and cancer chemoprevention: Investigating the action of triphenylselenonium chloride in in vivo models of mammary carcinogenesis. Anticancer Res 18: 9-12, 1998.
4. Lu, J, Jiang C, Kaeck M, Ganther H, Ip C and Thompson H: Cellular and metabolic effects of triphenylselenonium chloride in a mammary cell culture model. Carcinogenesis 16: 513-517, 1995.
5. 3-S-substituierten aromaten. Chem Ber 105: 3850-3864, 1972.
6. El-Bayoumy K, Chae Y-H, Upadhaya P, Meschter C, Cohen LA and Reddy BS: Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 52: 2402-2407, 1992.
7. Tiecco M, Testaferri L, Tingoli M, Chianelli D and Montanucci M: Nucleophilic aromatic substitutions of unactivated aryl halides by methyl selenide anions. Synthesis and selective dealkylations of aryl alkyl selenides. J Org Chem 48: 4289-4296, 1983.
8. Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 107: 1340-1348, 1977.
9. Horvath PM and Ip C: Synergistic effect of vitamin E and selenium in chemoprevention of mammary carcinogenesis in rats. Cancer Res 43: 5335-5341, 1983.
10. Olson OE, Palmer IS and Carey EE: Modification of the official fluorometric method for selenium in plants. J Assoc Offic Anal Chem 55: 117-121, 1975.
11. Burk RF and Hill KE: Regulation of selenoproteins. Ann Rev Nutr 13: 65-81, 1993.
12. Ip C, Hayes C, Budnick RM and Ganther HE: Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51: 595-600, 1991.
13. Ip C and Lisk DJ: Bioavailability of selenium from selenium-enriched garlic. Nutr Cancer 20: 129-137, 1993.
14. Paglia DE and Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169, 1967.
15. Biegon A, Brewster M, Degani H, Pop E, Somjen D and Kaye AM: A permanently charged Tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Cancer Res 56: 4328-4331, 1996.
16. Ganther HE and Lawrence JR: Chemical transformations of selenium in living organisms. Improved forms of selenium for cancer prevention. Tetrahedron 55: 12299-12310, 1997.
17. Ip C, El-Bayoumy K, Upadhyaya P, Ganther H, Vadhanavikit S and Thompson H: Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis 15: 187-192, 1994.
18. Ip C and Ganther H: Relationship between chemical form of selenium and anticarcinogenic activity. In: Cancer Chemoprevention (Eds. Wattenberg L, Lipkin M, Boone CW and Kelloff GJ), pp. 479-488. CRC Press, Boca Raton, FL, 1992.